A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Astra and Pfizer make the case for next-generation booster vaccines, which for the UK group at least could have important financial implications.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.